anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To provide particulate contrast media for use in CT imaging.SOLUTION: The contrast media are based on particles of low-Z elements. In an exemplary embodiment, the invention provides an enteric contrast medium formulation. An exemplary formulation comprises (a) an enteric contrast medium comprising essentially water-insoluble particles of a material selected from microparticles and nanoparticles. Exemplary particles comprise a material comprising a plurality of atoms of an element with an atomic number from 6 to 52. In various embodiments, the particles are coated with a material compatible with enteric administration of the formulation to a subject in need of such administration. In an exemplary embodiment, the contrast medium is incorporated into a pharmaceutically acceptable vehicle in which the particles are suspended. The invention also provides methods for imaging of body parts simultaneously enhanced with contrast media of the invention and with other contrast media of a different type using CT imaging, including dual energy or spectral CT imaging. The invention also provides methods for the digital separation of CT signal produced by the contrast media of the invention from the CT signal produced by other contrast media or bodily tissues, to generate multiple resultant CT images with individual contrast materials subtracted or highlighted.SELECTED DRAWING: None
Post-COVID syndrome (PCS) patients have reported a wide range of symptoms, including fatigue, shortness of breath, and diarrhea. Particularly, the presence of gastrointestinal symptoms has led to the hypothesis that the gut microbiome is involved in the development and severity of PCS. The objective of this review is to provide an overview of the role of the gut microbiome in PCS by describing the microbial composition and microbial metabolites in COVID-19 and PCS. Moreover, host-microbe interactions via the microbiota-gut-brain (MGB) and the microbiota-gut-lung (MGL) axes are described. Furthermore, we explore the potential of therapeutically targeting the gut microbiome to support the recovery of PCS by reviewing preclinical model systems and clinical studies. Overall, current studies provide evidence that the gut microbiota is affected in PCS; however, diversity in symptoms and highly individual microbiota compositions suggest the need for personalized medicine. Gut-targeted therapies, including treatments with pre- and probiotics, have the potential to improve the quality of life of affected individuals.
Although preoperative chemoradiation therapy followed by surgery is the most common approach for patients with resectable esophageal cancer, considerable number of esophageal cancer patients received operation as the first treatment modality. Accordingly, postoperative treatments have always been playing an important role because of the poor survival rates of the patients in stage ⅡB\[UICC 7th edition\] -Ⅲ\[UICC 7th edition\] who have been treated with resection alone. The existing data shows that the 5-yeal survival rate of stageⅡB-Ⅲ of thoracic esophageal squamous cell carcinoma(TESCC) after surgery is merely about 28.4% ,and locoregional lymph nodes metastases is responsible for the main cause of failure. While we have proved the value of prophylactic radiation therapy after radical esophagectomy for esophageal carcinoma with positive lymph node metastases and stage Ⅲ disease (UICC 6th edition) under the conventional 2-dimensional radiotherapy methods in subset analysis of prospective randomized clinical trial. For patients with positive lymph nodes, 5 year survival after surgery alone was 28.4%, median overall survival was 24 months, recurrence patterns were 34.6% in mediastinal lymph nodes，13.3% in supraclavicular lymph nodes，10% in abdominal lymph nodes. Distant metastases occurred in 21% patients. Adjuvant radiotherapy significantly reduced the recurrence in mediastinal lymph nodes(13.4%), supraclavicular lymph nodes (6.1%). However distant metastases rate increased to 30.7%. Chemotherapy may be vital for these patients. Chen reported that 5 year overall survival rates for the chemoradiotherapy group and radiotherapy group were 47.4% and 38.6% (P=0.03). Based on our studies, treatment failure occurred in 8% patients because of celiac metastases. Small radiation field by omitting celiac drainage region may ensure patients to accept 2 cycles of concurrent chemotherapy for lower toxicity.
The invention provides a medicine for remedying cancer, in particular to a medicine for remedying various cancers after surgery. The medicine is characterized in that No. I recipe takes radix rehmanniae, red peony root, bletilla, Szechwan lovage rhizome, wine-madder, salvia, panpax notoginseng, dandelion, APN, rhodiola himalensis, raw radix astragali, angelica, wolfberry fruit, chinese yam, radixpseudostell, membrane of chicken gizzard, asparagus, trichosanthin, hawthorn and so on as raw materials; No. II recipe takes vinegar leaching and frying turtle shell, dried lacquer, duchesnea indica,citrus aurantium, earth frying atractylodes, areca nut, mythic fungus, dodder, sang, raw ochre, pubescent holly, honeysuckleand so on as raw materials; No. III recipe takes sang, liriope, liquorices,cinnamon, herba cistanches, wolfberry fruit and so on as raw materials. The recipes are separately made into decoction in proportion. The medicine uses the comprehensive effect of each medicine to remedy various cancers that have been processed with surgery. The medicine can remove blood heat, influence blood, active blood without randomly influencing, stop blood, eliminate blood stasis, produce new blood and drain deteriorated blood without harm to new blood. The clinical treatment shows that the medicine has significant efficacy.
Body Mass Index (WHO) established by WHO. BMI \< 25 has been defined as 'normal weight'.
The invention discloses the Phellinus igniarius (L. ex Fr.) Quel. application as tumor; prepared medicine has preferable curative effect to tumors such as hepatocarcinoma, pulmonary carcinoma, bladder cancer, colon cancer, cervical cancer, breast carcinoma, leukemia, lymphatic cancer, human osteosarcoma, carcinoma of prostate, gastrointestinal stromal tumors (GISTs); it is not only Phellinus igniarius (L. ex Fr.) Quel. application in preparing antitumor drug and clinical expansion provides theoretical foundation; and comprehensive utilization and industrialized development to Phellinus igniarius (L. ex Fr.) Quel. resource is significant, has important economic benefit and social benefit.
Isoproterenol hydrochloride injection should generally be started at the lowest recommended dose. This may be gradually increased if necessary while carefully monitoring the patient. Doses sufficient to increase the heart rate to more than 130 beats per minute may increase the likelihood of inducing ventricular arrhythmias. Such increases in heart rate will also tend to increase cardiac work and oxygen requirements which may adversely affect the failing heart or the heart with a significant degree of arteriosclerosis.

Adequate filling of the intravascular compartment by suitable volume expanders is of primary importance in most cases of shock and should precede the administration of vasoactive drugs. In patients with normal cardiac function, determination of central venous pressure is a reliable guide during volume replacement. If evidence of hypoperfusion persists after adequate volume replacement, isoproterenol hydrochloride injection may be given.

In addition to the routine monitoring of systemic blood pressure, heart rate, urine flow, and the electrocardiograph, monitor the response to therapy by frequent determination of the central venous pressure and blood gases. Closely observe patients in shock during isoproterenol hydrochloride injection administration. If the heart rate exceeds 110 beats per minute, it may be advisable to decrease the infusion rate or temporarily discontinue the infusion. Determinations of cardiac output and circulation time may also be helpful. Take appropriate measures to ensure adequate ventilation. Pay attention to acid-base balance and to the correction of electrolyte disturbances.
### Teratogenic Effects. Pregnancy Category C 

Teratogenic studies were conducted in mice and rats at dosages of 0.5, 1, 2, and 4 mg/kg/day. Except for retarded fetal ossification at 4 mg/kg/day considered secondary to the decreased average fetal weights, no increase in fetal malformations was observed as compared with control groups. Other studies in mice reported in the literature using higher doses (5 to 15 mg/kg/day) have described maternal toxicity and death, increased fetal resorptions, and fetal malformations. Comparable studies in rodents using high doses of aspirin have shown similar maternal and fetal effects. However, animal reproduction studies are not always predictive of human response. There are no adequate and well controlled studies in pregnant women. 

Indomethacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### Nonteratogenic Effects

Because of the known effects of non-steroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.

The known effects of indomethacin and other drugs of this class on the human fetus during the third trimester of pregnancy include: constriction of the ductus arteriosus prenatally, tricuspid incompetence, and pulmonary hypertension; nonclosure of the ductus arteriosus postnatally which may be resistant to medical management; myocardial degenerative changes, platelet dysfunction with resultant bleeding, intracranial bleeding, renal dysfunction or failure, renal injury/dysgenesis which may result in prolonged or permanent renal failure, oligohydramnios, gastrointestinal bleeding or perforation, and increased risk of necrotizing enterocolitis.

In rats and mice, 4 mg/kg/day given during the last 3 days of gestation caused a decrease in maternal weight gain and some maternal and fetal deaths. An increased incidence of neuronal necrosis in the diencephalon in the live born fetuses was observed. At 2 mg/kg/day, no increase in neuronal necrosis was observed as compared to the control groups. Administration of 0.5 or 4 mg/kg/day during the first 3 days of life did not cause an increase in neuronal necrosis at either dose level.
Hoof diseases are a major welfare and economic issue in the global dairy cattle production industry, which can be minimized through improved management and breeding practices. Optimal genetic improvement of hoof health could benefit from a deep understanding of the genetic background and biological underpinning of indicators of hoof health. Therefore, the primary objectives of this study were to perform genome-wide association studies, using imputed high-density genetic markers data from North American Holstein cattle, for 8 hoof-related traits: digital dermatitis, sole ulcer, sole hemorrhage, white line lesion, heel horn erosion, interdigital dermatitis, interdigital hyperplasia, and toe ulcer, and a hoof health index. De-regressed estimated breeding values from 25,580 Holstein animals were used as pseudo-phenotypes for the association analyses. The genomic quality control, genotype phasing, and genotype imputation were performed using the PLINK (version 1.9), Eagle (version 2.4.1), and Minimac4 software, respectively. The functional genomic analyses were performed using the GALLO R package and the DAVID platform. We identified 22, 34, 14, 22, 28, 33, 24, 43, and 15 significant markers for digital dermatitis, heel horn erosion, interdigital dermatitis, interdigital hyperplasia, sole hemorrhage, sole ulcer, toe ulcer, white line lesion disease, and the hoof health index, respectively. The significant markers were located across all autosomes, except BTA10, BTA12, BTA20, BTA26, BTA27, and BTA28. Moreover, the genomic regions identified overlap with various previously reported quantitative trait loci for exterior, health, meat and carcass, milk, production, and reproduction traits. The enrichment analyses identified 44 significant gene ontology terms. These enriched genomic regions harbor various candidate genes previously associated with bone development, metabolism, and infectious and immunological diseases. These findings indicate that hoof health traits are highly polygenic and influenced by a wide range of biological processes.
The present invention relates to Shuangjinlian oral liquid for treating common cold and influenza and a preparation method thereof. The present invention is characterized in that The Shuangjinlian oral liquid is prepared from the following raw materials (weight ratio): 10 to 40 % of double blossom (honeysuckle flower), 10 to 25 % of Chinese globeflower flower, 10 to 25 % of scutellaria root, 20 to 40 % of forsythia fruit and 15 to 30 % of bupleurum root. Compared with the prior art, the Shuangjinlian oral liquid has the advantages of high content of effective components and low prescription dosage, and can inhibit various influenza viruses and various germs. Simultaneously, the present invention has the advantages of high speed of removing heat, pain alleviation and obvious effect of relieving cough. By clinical test, a patient takes the Shuangjinlian oral liquid of the present invention an hour later, and the heat is removed; a patient can return to normal temperature seven hours later. The Shuangjinlian oral liquid has the obvious effects of alleviating pain and relieving cough. The Shuangjinlian oral liquid is better than a medicine for removing heat and alleviating pain in the western medicine, and the functions of taking a temporary solution and effecting a permanent cure of the Shuangjinlian oral liquid are obviously better than those of the western medicine.
Participants in the experimental group performed one session of 30% 1RM with Practical blood flow restriction training. The number of repetitions in every set was 15 times with PBFR.19 Participants in the experimental group used the elite band (occlusion training bands) for both thighs during the training session. The width of the thigh band was 5cm, which would produce a pressure between 160-240 mmHg. This pressure range is appropriate for most of the individuals who used PBFR.27 The perceived pressure scale (PPS) was used to estimate the appropriate pressure (7 out of 10) in training before performing the exercises.28,29 The blood flow restriction bands booklet was used30 along with previous studies to design the training session. Participants removed the BFR band immediately after the end of the training session.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to pharmaceutical industry, particularly to an oral care composition that contains an active compound of magnolia Cortex extract and an anticalculous system including tetrasodium-pyrophosphate (TSPP) and sodium-tripoliphosphate (STPP) taken in certain amount. The method for prevention of dental deposit and dental calculus on an oral surface. The method to stimulate or maintain the in an individual. The oral care composition containing an antibacterial component including magnolia Cortex extract, and safe and effective amount of the anticalculous system consisting of tetrasodium-pyrophosphate (TSPP), sodium-tripoliphosphate (STPP), copolymer of maleic anhydride and methyl vinyl ester, and a carrier acceptable for oral introduction. The method of treating dental deposit and dental calculus on the oral surface. The oral care composition containing the antibacterial component including at least one active compound of magnolia Cortex extract; safe and effective amount of anticalculous system including tetrasodium-pyrophosphate (TSPP) and sodium-tripoliphosphate (STPP), and the carrier acceptable for oral introduction. ^ EFFECT: compositions are effective for oral care, exhibit antideposit, anticalculous, and antigingivitis action. ^ 27 cl, 2 tbl, 2 ex
We will mail informational materials to individuals with SCI/D in our control group at the same timepoints over 6 months as our intervention letter mailings. The informational materials will discuss life domains that are important to a good quality of life. Topics include community living, physical/healthy living, safety and security, social/spirituality, advocacy/engagement, and employment/volunteering. We will draw information for each topic from the Knowledge Translation Center SCI Factsheets (MSKTC 2021) and the LifeCourse Nexus library (2021).
The invention discloses a detection method for a Chinese medicinal composition preparation. The Chinese medicinal composition preparation is prepared by adding raw material medicaments and adding conventional auxiliary materials, and is prepared into various preparation forms acceptable pharmaceutically by the conventional process. The detection method comprises the steps of identification and content measurement. In the identification step, thin-layer chromatographies of imperatorin and isomperatorin in dahurian angelica root and magnoline in biond magnolia flower are identified, and by reexamination, the thin-layer chromatographies have clear spots, good repeatability and no interference in the blank. And at the same time, in the content measurement step, the content of magnoline in biond magnolia flower is measured by adopting a high efficiency liquid chromatography method, and the result shows that a chromatographic peak and an impurity peak of magnoline can be better separated. The quality control of the invention improves the stability of the product and is beneficial for the quality control of the industrial production.
A woman in her late 50s on mycophenolate for limited systemic sclerosis presented with abdominal pain. Vital signs and investigative evaluations were normal. Cross-sectional imaging identified gastric and small bowel wall thickening, free fluid, and pneumoperitoneum. In the operating room, a small bowel perforation was found and resected. Postoperatively, immunosuppression was held and she completed a course of amoxicillin/clavulanate. She discharged home and re-presented on postoperative day 8 with seizures and was found to have a frontal brain mass which was biopsied. Pathology from both the resected bowel and brain biopsy demonstrated Epstein-Barr virus-positive B-cell lymphoproliferative disorder with polymorphic B-cell features. The patient's immunosuppression was discontinued, and she was enrolled in a clinical trial for chemotherapy. Lymphoproliferative disorder can present years after immunosuppression initiation with either spontaneous perforation or solid tumour. Pathological assessment determines treatment options. Heightened concern for atypical clinical presentations in immunosuppressed patients is always warranted.
Treatment development for cocaine dependence often proceeds without effort to adapt treatment parameters to patient characteristics. Such a one-size-fits-all approach is problematic because of the heterogeneity of the clinical population. Additionally, the approach is often subject to opposing biases either towards constraining costs or maximizing efficacy. This project includes two sequential clinical trails examining variations of the CRA + Vouchers treatment for cocaine dependence that are designed to explore matching treatment parameters to patient baseline characteristics known to moderate treatment response among cocaine-dependent outpatients. In Trial 1, all patients were randomly assigned to receive 24 weeks of CRA therapy but randomly assigned to one of three voucher-based incentive conditions: (a) 6 weeks of vouchers contingent on abstinence and incentive monetary value at usual level; (b) 6 weeks of vouchers contingent on abstinence but incentive value set at usual level for low-severity patients (intranasal cocaine users or married patients) and at twice the usual value for high severity patients (i.e., unmarried cocaine smokers/injectors), or to (c) a control condition where incentives were provided independent of recent cocaine use. In Trial 2, all patients receive 12 weeks of abstinence-contingent incentives, but randomly assigned to also receive (a) 24 weeks of CRA therapy or (b) 4 weeks of CRA therapy. The overarching goal of the two trials is to strike a balance between the aforementioned biases towards constraining costs or maximizing efficacy and thereby facilitate cost containment without compromising efficacy, especially among more severe patients.
More than 400,000 TKAs are performed each year in the United States to alleviate pain and disability associated with knee OA. Although this procedure reliably reduces pain and improves function in people with knee OA, recovery of the strength of the quadriceps muscle to normal levels is rare. For years after a TKA, performance while walking or while doing a more physically demanding activity, such as stair climbing, is also significantly lower in people who have had a TKA than in healthy adults of the same age. Within the past few years, less invasive TKA surgical techniques have been developed as promising alternatives to traditional TKA. Minimally invasive TKA, or TKA(min), achieves the same surgical objectives, but possibly without doing as much damage to the quadriceps muscle as is seen with traditional TKA. No studies, however, have specifically investigated how TKA(min) might preserve quadriceps muscle function. This study will determine whether TKA(min) is better than TKA at improving quadriceps muscle force production and activation, increasing knee range of motion, and reducing post-operative pain to improve overall functional outcomes.

Participants who are scheduled to undergo knee replacement surgery will be randomly assigned to receive either traditional TKA or TKA(min). Prior to surgery, participants will attend a 30-minute orientation session and undergo certain tests to evaluate knee function. Functional testing will include timed walking, stair climbing, balance testing, and knee flexibility measurements. Other evaluations will include thigh muscle strength and activation testing, which uses brief electrical pulses to determine if the muscles are contracted as much as possible, and health status questionnaires. After the operation, participants will be instructed to use walking aids, such as a walker, crutches, or a cane, for a period of time. Participants will attend study visits for repeat testing 48 hours following surgery; at Months 1, 3, and 6; and at Years 1 and 2.
Different from other previous researches, the research discusses the action mechanism of catalpol extract on treating type 2 diabetes mellitus by applying a biological method. Taking skeletal muscle cells as an experimental object, constructing an experimental group for blocking a P13/Akt signal pathway, then administering catalpol extract, analyzing the expression of related carbohydrate genes of the liver cells, and discussing the cell mechanism of the catalpol extract on the treatment of type 2 diabetes. At present, the research is not reported at home and abroad. The catalpol extract provides a novel therapeutic approach. The method can save much expenses for purchasing db/db mice and double-gene knockout mice. The research detects the influence of catalpol extract on the insulin sensitivity of mouse myoblast cell strain (C2C12) by measuring the protein expression level of an insulin receptor substrate P-IRS-1, and provides a theoretical basis for the treatment of type 2 diabetes.